Evercore ISI analyst Vijay Kumar upgraded Revvity to Outperform from In Line with a price target of $125, up from $88. China growing with minimal CapEx exposure and a biopharma turn makes the setup “interesting,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RVTY:
